Posted by Michael Wonder on 08 Dec 2017
Aptinyx granted fast track designation, initiates Phase 1 for second clinical candidate, NYX-783, in post-traumatic stress disorder
7 December 2017 - Data presented at American College of Neuropsychopharmacology Annual Meeting demonstrate robust and durable response in models relevant to PTSD.
Aptinyx today announced fast track designation, new data, and initiation of Phase 1 clinical development for its second clinical candidate to modulate N-methyl-D-aspartate (NMDA) receptors, NYX-783, in post-traumatic stress disorder. The data were presented at the annual meeting of the American College of Neuropsychopharmacology.
Aptinyx has initiated a Phase 1 clinical study to evaluate the safety and tolerability of NYX-783 in healthy volunteers and plans to advance the compound into studies to evaluate efficacy next year.
